{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T09:27:02Z","timestamp":1718962022627},"reference-count":29,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3960\/jslrt.54.187","type":"journal-article","created":{"date-parts":[[2014,12,14]],"date-time":"2014-12-14T23:18:21Z","timestamp":1418599101000},"page":"187-196","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Features and Outcomes of 9 Patients with Immunodeficiency-Associated Lymphoproliferative Disorders Treated at a Single Institution"],"prefix":"10.3960","volume":"54","author":[{"given":"Noriaki","family":"Kawano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanshiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Himeji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Shimao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Marutsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Emery P: Treatment of rheumatoid arthritis. BMJ 332:152-155, 2006","DOI":"10.1136\/bmj.332.7534.152"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Sokka T, Envalds M, Pincus T: Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 18:228-239, 2008","DOI":"10.3109\/s10165-008-0056-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, <i>et al<\/i>.: Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909-920, 2011","DOI":"10.1136\/ard.2010.144998"},{"key":"4","unstructured":"4 Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, <i>et al<\/i>.: Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 21:122-133, 2011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Salliot C, van der Heijde D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100-1104, 2009","DOI":"10.1136\/ard.2008.093690"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Wessels JA, Huizinga TW, Guchelaar HJ: Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47:249-255, 2008","DOI":"10.1093\/rheumatology\/kem279"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L: Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16:254-261, 2004","DOI":"10.1097\/00002281-200405000-00014"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740-1751, 2004","DOI":"10.1002\/art.20311"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Weyand CM, Goronzy JJ, Kurtin PJ: Lymphoma in rheumatoid arthritis: an immune system set up for failure. Arthritis Rheum 54:685-689, 2006","DOI":"10.1002\/art.21674"},{"key":"10","unstructured":"10 WHO Classification of Tumours, Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, <i>et al<\/i>. (eds): 4th ed, Lyon, IARC, 2008"},{"key":"11","unstructured":"11 Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, <i>et al<\/i>.: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99:3909-3915, 2002"},{"key":"12","unstructured":"12 Hoshida Y, Tomita Y, Zhiming D, Yamauchi A, Nakatsuka S, <i>et al<\/i>.: Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 108:443-449, 2004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Niitsu N, Okamoto M, Nakamine H, Hirano M: Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci 101:1309-1313, 2010","DOI":"10.1111\/j.1349-7006.2010.01517.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kojima M, Motoori T, Nakamura S: Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother 60:663-672, 2006","DOI":"10.1016\/j.biopha.2006.09.004"},{"key":"15","unstructured":"15 Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, <i>et al<\/i>.: Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91:20-28, 2013"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, <i>et al<\/i>.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002","DOI":"10.1056\/NEJMoa011795"},{"key":"17","unstructured":"17 Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, <i>et al<\/i>.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d&apos;Etude des Lymphomes de l&apos;Adulte. J Clin Oncol 23:4117-4126, 2005"},{"key":"18","unstructured":"18 Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, <i>et al<\/i>.: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013-1022, 2011"},{"key":"19","unstructured":"19 Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, <i>et al<\/i>.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d&apos;Etudes des Lymphomes de l&apos;Adulte. Blood 116:2040-2045, 2010"},{"key":"20","unstructured":"20 Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, <i>et al<\/i>.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70:39-46, 2011"},{"key":"21","unstructured":"21 Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, <i>et al<\/i>.: Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71:351-357, 2012"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Kawano N, Ono N, Yoshida S, Kuriyama T, Yamashita K, <i>et al<\/i>.: Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration. J Clin Exp Hematop 52:193-198, 2012","DOI":"10.3960\/jslrt.52.193"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, <i>et al<\/i>.: Report of an international workshop to standardize response criteria for non-Hodgkin&apos;s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"24","unstructured":"24 Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, <i>et al<\/i>.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631-637, 2010"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 A predictive model for aggressive non-Hodgkin&apos;s lymphoma. The International Non-Hodgkin&apos;s Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993","DOI":"10.1056\/NEJM199309303291402"},{"key":"26","unstructured":"26 Solal-C\u00e9ligny P: Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden. Anticancer Drugs Suppl 2:S11-14, 2001"},{"key":"27","unstructured":"27 Rothe A, Schulz H, Elter T, Engert A, Reiser M: Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin&apos;s lymphoma. Haematologica 89:875-876, 2004"},{"key":"28","unstructured":"28 Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, <i>et al<\/i>.: Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. Cancer Sci 102:1698-1705, 2011"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Griffin MM, Morley N: Rituximab in the treatment of non-Hodgkin&apos;s lymphoma-A critical evaluation of randomized controlled trials. Expert Opin Biol Ther 13:803-811, 2013","DOI":"10.1517\/14712598.2013.786698"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:47Z","timestamp":1621540007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/54\/3\/54_187\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.54.187","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}